敲减骨桥蛋白对吉非替尼耐药的非小细胞肺癌PC9细胞凋亡的研究

doi:10.11904/j.issn.1002-3070.2022.04.004

Abstract

Abstract: Objective The aim of this study was to investigate the role and mechanism of osteopontin in mediating epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs)resistance in NSCLC.Methods The PC9R cells with osteopontin knockdown was the treatment group,and untreated PC9R cells was the control group.Quantitative real time PCR (RT-qPCR) and Western blot(WB)were carried out to check the expression of osteopontin and apoptosis related proteins in NSCLC cells.Mitochondrial membrane potential measurement assay were performed to check the mitochondria fucntion.The cell counting kit-8(CCK-8)and EdU incorporation assays were used to measure cell proliferation.Results The results showed that osteopontin was significantly up-regulated in gefitinib-resistant PC9R cells compared with PC9 cells(1.00±0.05 vs. 5.12±0.12,P＜0.01).Knockdown of osteopontin induced mitochondria dysfunction and apoptosis related proteins were over expressed(8.34±0.96 vs. 48.56±3.34,P＜0.05).Knockdown of osteopontin inhibted PC9R cells prolifereation.Therefore,our results further demonstrated osteopontin promted PC9R cells apoptosis.Conclusion Knockdown osteopontin induced mitochondrial dysfunction and induced the apoptosis of gefitinib-resistant cells.Knockdown osteopontin increases the sensitivity of lung cancer cells to gefitinib.

Key words: Osteopontin, Apoptosis, Tyrosine kinase inhibitors, Resistance

CLC Number:

R734.1

WEN Xiaoxing, LIU Dahai, WU Xuehui, WANG Bingping, FANG Tao. Knockdown osteopontin promotes gefitinib-resistence PC9 cells apoptosis[J]. Journal of Practical Oncology, 2022, 36(4): 310-315.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.04.004

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I4/310

References

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Duma N,Santana-Davila R,Molina JR.Non-small cell lung cancer:epidemiology,screening,diagnosis,and treatment[J].Mayo Clin Proc,2019,94(8):1623-1640.
3 Remon J,Hendriks LEL,Cardona AF,et al.EGFR exon 20 insertions in advanced non-small cell lung cancer:a new history begins[J].Cancer Treat Rev,2020,90:102105.
4 刘迪,龙谦,罗猛,等.骨桥蛋白介导PI3K/AKT通路促进非小细胞肺癌顺铂耐药[J].华中科技大学学报:医学版,2020,49(1):17-23.
5 Wang YJ,Wang QW,Yu DH,et al.Osteopontin improves sensitivity to tyrosine kinase inhibitor in lung adenocarcinoma in vitro by promoting epidermal growth factor receptor phosphorylation[J].J Cancer Res Clin Oncol,2021,147(11):3245-3254.
6 Fu Y,Zhang Y,Lei Z,et al.Abnormally activated SPP1/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer[J].J Hematol Oncol,2020,13(1):169.
7 Zhou J,Qu G,Zhang G,et al.Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway[J].J Exp Clin Cancer Res,2019,38(1):96.
8 Wu SG,Shih JY.Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer[J].Mol Cancer,2018,17(1):38.
9 Hsu WH,Yang JC,Mok TS,et al.Overview of current systemic management of EGFR-mutant NSCLC[J].Ann Oncol,2018,29:3-9.
10 Johnson M,Garassino MC,Mok T,et al.Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors:Focus on novel therapies[J].Lung Cancer,2022,170:41-51.
11 Wang Q,Yang S,Wang K,et al.MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer[J].J Hematol Oncol,2019,12(1):63.
12 Gusenbauer S,Vlaicu P,Ullrich A.HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors[J].Oncogene,2013,32(33):3846-3856.
13 Nilsson MB,Sun H,Robichaux J,et al.A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components[J].Sci Transl Med,2020,12(559):4589.
14 Lamort AS,Giopanou I,Psallidas I,et al.Osteopontin as a link between inflammation and cancer:The thorax in the spotlight[J].Cells,2019,8(8):815.
15 Donati V,Boldrini L,Dell'Omodarme M,et al.Osteopontin expression and prognostic significance in non-small cell lung cancer[J].Clin Cancer Res,2005,11(18):6459-6465.
16 任民柱,杨留勤.骨桥蛋白在肿瘤转移中的作用及机制[J].实用肿瘤学杂志,2010,24(2):186-189.
17 Wang X,Zhang F,Yang X,et al.Secreted phosphoprotein 1(SPP1)contributes to second-generation EGFR tyrosine kinase inhibitor resistance in non-small cell lung cancer[J].Oncol Res,2019,27(8):871-877.
18 Takeuchi S,Yano S.Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors:sensitivity and resistance[J].Respir Investig,2014,52(6):348-356.

[1]	YU Chengping, CUI Yongkang, LI Linqiang. Research progress of eccDNA in cancer [J]. Journal of Practical Oncology, 2022, 36(3): 255-258.
[2]	CHEN Dejia, LOU Ge. Research progress of Connexin26 in tumors [J]. Journal of Practical Oncology, 2022, 36(2): 162-166.
[3]	WANG Zongwen, LI Xiaodong, ZHU Qiankun, ZENG Shicong, ZHAI Bo. KIF14 in the mechanism of acquired drug resistance in hepatocellular carcinoma SMCC-7721 cells [J]. Journal of Practical Oncology, 2022, 36(1): 14-19.
[4]	JI Lei, JI Daolin, BAO Dongdong, TAN Gang. The latest research progress of long non-coding RNA in sorafenib resistance of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2021, 35(6): 562-567.
[5]	LI Na, DENG Qian, JIANG Jianjun. The role of NF-κB signaling pathway in chemotherapy resistance of malignant tumors [J]. Journal of Practical Oncology, 2021, 35(6): 580-584.
[6]	CHEN Xuejian, WANG Wei, ZHOU Jian, LI Ning, ZHANG Haopeng, XU Lishan. Research on the molecular mechanism of regorafenib combined with perifosine in inducing apoptosis of human hepatoma HepG2 cells [J]. Journal of Practical Oncology, 2021, 35(5): 408-413.
[7]	JIN Shengye, PANG Da. Research progress in the mechanism of oncolytic virus inducing tumor apoptosis and activating anti-tumor immunity [J]. Journal of Practical Oncology, 2021, 35(5): 462-467.
[8]	LI Yuying, ZHANG Yue. Research progress of Sirtuins in breast cancer [J]. Journal of Practical Oncology, 2021, 35(3): 277-281.
[9]	YIN Lei, YANG Xudong, YANG Yue, NIU Xingjian, ZHOU Xiaoping, JI Hongfei, WANG Yiran. The clinical significance and related mechanism of neutrophil to lymphocyte ratio in the prognostic evaluation of patients with non small cell lung cancer [J]. Journal of Practical Oncology, 2021, 35(2): 117-124.
[10]	HU Qihui, DU Yichao, HE Kai, FU Wenguang, XIA Xianming. The role of endoplasmic reticulum stress in liver cancer [J]. Journal of Practical Oncology, 2021, 35(2): 160-164.
[11]	YIN Qi, HU Yanjian, CUI Puze, HU Yanhua. Research progress of Notch signaling pathway in regulating apoptosis of tumor cells [J]. Journal of Practical Oncology, 2021, 35(2): 165-169.
[12]	GUO Piaoting, MIN Li, CHEN Jianjun, WANG Xin, NI Siyi. Salvianolic acid B regulates ROS to inhibit the proliferation and promote apoptosis in colorectal cancer HCT-116 cells [J]. Journal of Practical Oncology, 2020, 34(6): 504-510.
[13]	GUO Piaoting, ZOU Yang. LncRNA SOX2OT sponge adsorbs miR-34a to promote SOX2 expression and enhance multidrug resistance in colorectal cancer [J]. Journal of Practical Oncology, 2020, 34(5): 398-403.
[14]	HAN Jing, PU Yan, LIU Huibin. Effects of SKA1 on cell proliferation and apoptosis of renal cell carcinoma and its molecular mechanism [J]. Journal of Practical Oncology, 2020, 34(5): 404-411.
[15]	PANG Chen, ZHANG Xiuling, ZHANG Xiliu. Research progress in inhibitory epithelium-derived malignant tumors by dendrobium officinale [J]. Journal of Practical Oncology, 2020, 34(4): 362-367.

Knockdown osteopontin promotes gefitinib-resistence PC9 cells apoptosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments